U.S. markets open in 4 hours 56 minutes
  • S&P Futures

    4,158.00
    +27.50 (+0.67%)
     
  • Dow Futures

    34,195.00
    +200.00 (+0.59%)
     
  • Nasdaq Futures

    12,658.25
    +113.00 (+0.90%)
     
  • Russell 2000 Futures

    1,963.20
    +13.30 (+0.68%)
     
  • Crude Oil

    78.29
    -0.18 (-0.23%)
     
  • Gold

    1,892.00
    +1.30 (+0.07%)
     
  • Silver

    22.38
    -0.04 (-0.18%)
     
  • EUR/USD

    1.0760
    +0.0042 (+0.39%)
     
  • 10-Yr Bond

    3.6530
    0.0000 (0.00%)
     
  • Vix

    19.21
    +0.55 (+2.95%)
     
  • GBP/USD

    1.2126
    +0.0056 (+0.46%)
     
  • USD/JPY

    130.9560
    -0.3800 (-0.29%)
     
  • BTC-USD

    22,702.41
    -508.14 (-2.19%)
     
  • CMC Crypto 200

    522.73
    -14.16 (-2.64%)
     
  • FTSE 100

    7,942.02
    +56.85 (+0.72%)
     
  • Nikkei 225

    27,584.35
    -22.11 (-0.08%)
     

Esperion to Present Key Science at the American Heart Association Scientific Sessions 2021

ANN ARBOR, Mich., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the presentation of three abstracts at the American Heart Association (AHA) Scientific Sessions 2021 taking place on November 13-15, 2021.

AHA Scientific Sessions 2021

On Demand

Session Type:

Oral Presentation #266

Abstract Title:

Factors Associated with Enhanced Low-density Lipoprotein Cholesterol Lowering with Bempedoic Acid Among Patients Enrolled in Phase 3 Studies

Authors:

Christie M. Ballantyne, MD; Harold E. Bays, MD; Jeremy Smart, PharmD; Yang Zhang, PhD; Kausik K. Ray, MD, MPhil

Session Type:

Oral Presentation #267

Abstract Title:

Efficacy and Safety of Bempedoic Acid in Patients with Metabolic Syndrome

Authors:

Michael D. Shapiro, DO, MCR; Pam R. Taub, MD; Michael J. Louie, MD, MPH, MSc; Lei Lei, PhD; Christie M. Ballantyne, MD

Session Type:

Oral Presentation #264

Abstract Title:

Pharmacokinetics, Pharmacodynamics, and Safety of Bempedoic Acid in a Phase 1 Clinical Trial in Healthy Japanese, Chinese, and White Subjects

Authors:

Benny M. Amore, PhD; Rujun Teng, MS; Jeffrey C. Hanselman, MS

Bempedoic Acid

INDICATION
Bempedoic acid is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-C. Limitations of Use: The effect of bempedoic acid on cardiovascular morbidity and mortality has not been determined.

IMPORTANT SAFETY INFORMATION

Warnings and Precautions: Hyperuricemia: Bempedoic acid may increase blood uric acid levels. Hyperuricemia may occur early in treatment and persist throughout treatment, and may lead to the development of gout, especially in patients with a history of gout. Assess uric acid levels periodically as clinically indicated. Monitor for signs and symptoms of hyperuricemia, and initiate treatment with urate-lowering drugs as appropriate.

Tendon Rupture: Bempedoic acid is associated with an increased risk of tendon rupture or injury. In clinical trials, tendon rupture occurred in 0.5% of patients treated with bempedoic acid versus 0% of patients treated with placebo, and involved the rotator cuff (the shoulder), biceps tendon, or Achilles tendon. Tendon rupture occurred within weeks to months of starting bempedoic acid. Tendon rupture may occur more frequently in patients over 60 years of age, patients taking corticosteroid or fluoroquinolone drugs, patients with renal failure, and patients with previous tendon disorders. Discontinue bempedoic acid at the first sign of tendon rupture. Avoid bempedoic acid in patients who have a history of tendon disorders or tendon rupture.

Adverse Reactions: In clinical trials, the most commonly reported adverse reactions were upper respiratory tract infection, muscle spasms, hyperuricemia, back pain, abdominal pain or discomfort, bronchitis, pain in extremity, anemia, and elevated liver enzymes. Reactions reported less frequently, but still more often than with placebo, included benign prostatic hyperplasia and atrial fibrillation.

Drug Interactions: Simvastatin and Pravastatin: Concomitant use results in increased concentrations and increased risk of simvastatin or pravastatin-related myopathy. Use with greater than 20 mg of simvastatin or 40 mg of pravastatin should be avoided.

Lactation and Pregnancy: It is not recommended that bempedoic acid be taken during breastfeeding. Discontinue bempedoic acid when pregnancy is recognized, unless the benefits of therapy outweigh the potential risks to the fetus. Based on the mechanism of action, bempedoic acid may cause fetal harm.

Please see full Prescribing Information here.

Esperion Therapeutics
Esperion is The Lipid Management Company. Our goal is lipid management for everybody, that’s why we work hard to make our medicines easy to get, easy to take and easy to have. We discover, develop and commercialize innovative medicines and combinations to lower cholesterol, especially for patients whose needs aren’t being met by the status quo. Our entrepreneurial team of industry leaders is inclusive, passionate and resourceful. For more information, please visit www.esperion.com and follow us on Twitter at www.twitter.com/EsperionInc.

Forward-Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements relating to the expected closing of the exchange of the Notes pursuant to the Exchange Agreement and expectations regarding future transactions to further improve ESPERION’s balance sheet. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. The inclusion of forward-looking statements should not be regarded as a representation by ESPERION that any of these results will be achieved. Actual results may differ from those set forth in this Report due to the risks and uncertainties associated with the satisfaction of closing conditions under the Exchange Agreement and with entering into additional exchange agreements, as well as risks and uncertainties described in ESPERION’s filings with the U.S. Securities and Exchange Commission. Any forward-looking statements contained in this Report speak only as of the date hereof, and ESPERION disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by law. All forward-looking statements are qualified in their entirety by this cautionary statement.

Contact:
Corporate Communications
corporateteam@esperion.com